Fig. 6

TNF-α blocking reverses the effects of the IPF secreted factors. Infliximab (100–400 μg/ml) was added to fibroblasts cultured with normal (N-SN)/IPF (IPF-SN) supernatants and the effect on cell adhesion to fibronectin (FN) was tested (n = 5) (a). IPF/normal supernatants with/without Infliximab (400 μg/ml) were added to fibroblast cells seeded on plastic or fibronectin (FN) (10 μg/ml) coated plates and cell migration was tested (n = 4) (b). Results were normalized to control (N-SN) and considered significant * if p < 0.05, error bar represents the standard error. Representative photomicrographs of the scratch test assays (c). IPF/normal supernatants were added to fibroblast cells seeded on plastic or FN (10 μg/ml) coated plates for 30 min. PCNA (n = 4) and caspase-3 levels were tested by western blotting. Representative figure of 4 independent experiments (d)